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Summary
Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required
in the genesis of cancer. However, it remains uncertain whether apoptotic defects are essential for tumor maintenance.
To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic
leukemia. Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating
BCL-2 as a rational target for cancer therapy. Loss of this single molecule resulted in cell death, despite or perhaps
attributable to the presence of other oncogenic events. This suggests a generalizable model in which aberrations inherent
to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).
Introduction small cell lung cancer (Ben-Ezra et al., 1994), and melanoma
(Leiter et al., 2000).
The BCL-2 family of proteins is comprised of multidomainA myriad of genetic changes accompanies the evolution of a
normal cell to a cancer cell. These changes confer many abnor- antiapoptotic proteins (including BCL-2), multidomain proapo-
ptotic proteins (BAX, BAK), and the proapoptotic BH3-only pro-mal properties, including invasion and metastasis, cell cycle
aberrations, growth factor-independent proliferation, telomere teins (including BID, BAD, and BIM) (Danial and Korsmeyer,
2004). In response to selected death signals, individual proapo-preservation, angiogenesis, genomic instability, and resistance
to apoptosis (Green and Evan, 2002; Hanahan and Weinberg, ptotic BH3-only members are activated. Much of the intrinsic
pathway of apoptosis is focused at the surface of mitochondria,2000; Schmitt, 2003). These aberrations constitute modern mo-
lecular targets for developing cancer therapeutics. Yet, we have where BH3-only proteins either directly or indirectly induce the
oligomerization of proapoptotic BAX and BAK (Letai et al., 2002;only started to test which of the genetic changes selected for
during tumorigenesis are actually required to maintain that can- Wei et al., 2001). Subsequently, the mitochondrial outer mem-
brane is permeabilized, resulting in the release of cytochromecer (Chin et al., 1999; Felsher and Bishop, 1999; Gunther et al.,
2003; Huettner et al., 2000; Pelengaris et al., 1999). c, which forms an apoptosome complex with Apaf-1 and initiator
Caspase 9 to induce the activation of effector caspases (Li etBCL-2, the cardinal antiapoptotic oncogene, is located at
the chromosomal breakpoint of t(14;18) bearing human follicular al., 1997). By their proteolytic activity, the effector caspases
cause widespread cellular dysfunction and cell death. Antiapo-B cell lymphoma (Bakhshi et al., 1985; Cleary and Sklar, 1985;
Tsujimoto et al., 1985). Overexpressed BCL-2 opposes the apo- ptotic members like BCL-2 can disrupt this apoptotic program
by binding and sequestering BH3-only proteins, protecting BAXptotic death of cells and mice bearing a Bcl-2-Ig minigene reca-
pitulating the t(14;18) progress from follicular hyperplasia to high and BAK from oligomerization (Cheng et al., 2001).
Many of the abnormal properties of cancer cells mentionedgrade lymphoma (Hockenbery et al., 1990; McDonnell et al.,
1989; McDonnell and Korsmeyer, 1991; Vaux et al., 1988). High above violate physiological checkpoints within cells that theo-
retically would result in the generation of tonic death signals.levels of BCL-2 expression have been found in many cancers,
including follicular lymphoma (Gaulard et al., 1992), chronic This suggests that eliminating an antiapoptotic influence such
as BCL-2 from such cancers might unmask inherent death sig-lymphocytic leukemia (Schena et al., 1992), acute myelogenous
leukemia (Andreeff et al., 1999), myeloma (Harada et al., 1998), nals and result in cell death. To test whether BCL-2 is necessary
S I G N I F I C A N C E
Cancer cells possess many abnormalities that generate apoptotic signals. Moreover, genetic changes that impede apoptosis (such
as p53 loss or BCL-2 overexpression) result in cancer and are often found in cancer, supporting a role for blocking apoptosis during
tumorigenesis. Here we show that an apoptotic defect is also necessary for the unique stage of tumor maintenance. We demonstrate
that elimination of overexpressed BCL-2 rapidly induces apoptosis and remission of a B-lymphoblastic leukemia. This finding creden-
tials BCL-2 as a legitimate therapeutic target. Furthermore, it suggests that inherent, tonic death signals would kill cancer cells if the
apoptotic defect is eliminated.
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Figure 1. Construction of a conditional BCL-2 transgenic mouse
A: A conditional BCL- 2 allele. A human BCL-2 cDNA under the control of a minimal CMV promoter adjacent to a heptamer of the tet operon (tet-BCL-2)
locus was targeted into the DNA methyltransferase I (DMT1) locus. Shown is a schematic of the wt DMT1 locus, the 4 kb EcoRV to Bgl II targeting construct,
and final tet BCL-2 knockin DMT1 locus following cre-mediated deletion of the selectable marker. At bottom are representative Southern blots of correctly
integrated () and nontargeted () clones.
B: Doxycycline eliminates BCL-2 expression. Extracts from dissociated splenocytes from doubly transgenic mice were subjected to immunoblot for BCL-2.
Left two lanes are from mice that received no doxycycline; right two lanes are from mice that received 200 g/ml in drinking water for 2 weeks prior to
sacrifice.
for maintaining as well as developing a cancer, we generated not develop malignancies and demonstrated normal survival
(not shown).a mouse model in which the expression of BCL-2 is conditional.
Results tet-BCL-2/MMTV-tTA/E-myc mice
develop a lymphoblastic leukemia
Since BCL-2 oncogenesis requires additional aberrations, weA conditional BCL-2 trangene is tightly
controlled by doxycycline introduced deregulated c-myc, since this is a naturally occurring
secondary event known to complement BCL-2 in mouse andWe obtained germline transmission of a knockin allele in which
a human BCL-2 cDNA under the control of multimerized tet- human lymphomagenesis (Gauwerky et al., 1988; McDonnell
and Korsmeyer, 1991; Schmitt et al., 2000; Strasser et al., 1993;operons (Gossen et al., 1995) adjacent to a minimal CMV pro-
moter was targeted to the DNA methyltransferase1 (DMT1) locus Vaux et al., 1988). Mice singly transgenic for E-myc develop
a bulky B cell lymphoma, with a relatively normal white blood(tet-BCL-2) (Figure 1A). The DNA methyltransferase 1 (DMT1)
locus was chosen for its high rate of integration and consistent count (WBC) until late in the course of malignancy (Adams et
al., 1985). In a nonconditional model, mice expressing bothexpression patterns (Li et al., 1992). tet-BCL-2 mice were inter-
crossed with a line bearing the tetracycline transactivator (tTA) BCL-2 and c-myc under the control of the immunoglobulin en-
hancer (E) develop an immature lymphoblastic leukemia withinunder control of the MMTV promoter (MMTV-tTA), known to
express tTA in spleen as well as epithelial tissues (Hennighausen days of birth (Strasser et al., 1990). Similarly, our triply transgenic
(tet-BCL-2/MMTV-tTA/E-myc) mice uniformly developed lymph-et al., 1995; Huettner et al., 2000). Progeny bearing both alleles
(doubly transgenic) expressed BCL-2 in splenocytes and bone oblastic leukemia by 2 weeks of age (WBC 50,000/l). Over
weeks, the WBC rose to 2  105 to 2  106 per microliter.marrow cells as well as in epithelial cells, including mammary,
sebaceous, salivary, basal epidermal cells, thymic epithelium, The bone marrow was replaced with lymphoblasts expressing
human BCL-2 (Figures 2C–2F), which also infiltrated the spleenand testes (data not shown). BCL-2 expression was effectively
ablated when doxycycline was added to the drinking water (Figures 2A and 2B), resulting in marked splenomegaly (spleen
weight 5- to 10-fold  wt mice). Lymphoblasts effaced the(Figure 1B). At 18 months of age, doubly transgenic mice did
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CD4, HSA [Fraction D]) (Figure 3A). Four of 14 characterized
leukemias were less mature pre-pro-B cells (CD43, B220,
CD19, CD4, HSA [Fraction A1]) (Figure 3A; Allman et al.,
1999; Hardy and Hayakawa, 2001). To further assess the stage
of differentiation as well as clonality of the leukemias, we as-
sessed the configuration of immunoglobulin (Ig) heavy chain
gene loci. Pre-pro-B cell leukemias displayed a germline pattern,
as expected, whereas the pro-B to pre-B cell stage leukemias
demonstrated gene rearrangements indicative of monoclonal
or oligoclonal expansions of cells (Figure 3B). As a further as-
sessment of clonality and genomic instability, spectral karyo-
types (SKY) were performed. A representative karyotype of a
pro-/pre-B cell stage leukemia revealed clonal abnormalities
and evidence for genomic instability, including extra chromo-
somes 6 and 12 (Figure 3C).
BCL-2 is required for leukemia maintenance
To assess whether BCL-2 is required to maintain lymphoblastic
leukemia, we followed a matched cohort of 5- to 7-week-old
triply transgenic mice with leukemia, 14 of which received doxy-
cycline and 14 of which remained untreated. Administration of
doxycycline reduced the level of BCL-2 in peripheral mononu-
clear cells within 3 days (Figure 4A) and resulted in a dramatic
reduction in the WBC (Figures 4B–4D). Mice treated with doxy-
cycline, with only one exception, normalized their WBC over 10
days of treatment (Figure 4B). A subsequent cohort of mice
revealed that the bone marrow was no longer replaced by leuke-
mic lymphoblasts and demonstrated the resumption of normal
trilineage hematopoiesis (Figures 4E and 4F). Moreover, within
2 weeks of treatment, the spleen returned to normal (Figure 4G).
Apoptosis of lymphoblasts was noted in the bone marrow
of mice 48 hr following initiation of doxycycline (Figures 5A and
5B). Addition of doxycycline to cultured primary leukemia cells
from the bone marrow of triply transgenic mice resulted in apo-
ptotic death, providing evidence for a cell-autonomous effect
of eliminating BCL-2 (Figure 5C). Leukemic mice that demon-
strated overt signs of illness (lethargy, hunched posture, tachyp-
nea, and loss of skin turgor) resumed normal activity when the
Figure 2. Leukemic cell involvement of spleen, bone marrow, lymph node,
WBC returned to normal. However, the WBC did not decline inand liver
the untreated cohort, all of which died within 9 weeks of initiatingA: Splenic white and red pulp from tet-BCL-2/MMTV-tTA/E-myc mouse is
the study (Figures 4B and 6A). The doxycycline-treated micereplaced by leukemic infiltrate with evidence of extramedullary hematopoi-
esis (lower right), hematoxylin and eosin (HE). demonstrated a substantially improved median survival of 145
B: Normal appearance of spleen in tet-BCL-2/MMTV-tTA transgenic mouse. days versus 82 days for the untreated cohort and a significantly
C: Bone marrow from tet-BCL-2/MMTV-tTA/E-myc mouse is replaced with altered survival plot (p  0.000123; Figure 6A). While all un-
leukemic cells, HE. Compare with normal bone marrow in D.
treated mice died by just over 100 days of age, five doxycycline-D: Normal bone marrow from tet-BCL-2/MMTV-tTA mouse displaying trilin-
treated mice survived 200 days, and one has survived longereage hematopoiesis, HE.
E: Immunohistochemistry detects human BCL-2 in leukemic cells of bone than 1 year. Comparison of these cohorts demonstrates that
marrow from tet-BCL-2/MMTV-tTA/E-myc mouse. elimination of BCL-2 expression clearly resulted in remission of
F: Human BCL-2 is detected only in a minority of cells in bone marrow from
the leukemia and prolonged survival of the mice.tet-BCL-2/MMTV-tTA mouse.
The late deaths of doxycycline-treated triply transgenic miceG: Leukemia cells from tet-BCL-2/MMTV-tTA/E-myc mouse efface lymph
node architecture and invade adjacent fat, HE. resulted from a bulky B cell lymphoma, essentially indistinguish-
H: Leukemic cells from tet-BCL-2/MMTV-tTA/E-myc mouse invade liver, able in phenotype, histology, WBC, and tissue distribution to
HE. that developing in singly transgenic E-myc mice (Adams et
al., 1985). Moreover, the time of onset of these tumors and the
median survival of doxycycline-treated triply transgenic mice
(145 days) is also comparable to that of the 15 singly transgeniclymph node architecture (Figure 2G) and often infiltrated other
E-myc mice (146 days) followed in our study, and their survivaltissues including the liver (Figure 2H).
curves do not differ significantly (p  0.55; Figure 6A). TheseImmunophenotypic analysis revealed that all leukemic cells
late-onset B cell lymphomas would be expected since the con-were of B lymphocyte origin. The majority of leukemias repre-
stitutive c-myc transgene expression continues unabated, as itsented a continuum from pro-B cell (CD43, B220, CD19,
CD4, HSA [Fraction C]) to pre-B cells (CD43, B220, CD19, is not responsive to doxycycline. Only an occasional late-onset
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Figure 3. Leukemias are clonal lymphoblastic
leukemias
A: Immunophenotype of representative leuke-
mias. A pre-pro [Fraction A1] (CD43, B220,
CD19, CD4, HSA) and a pro to pre [Fraction
C-D] (CD43var, B220, CD19, CD4, HSA) leuke-
mia are shown.
B: Southern analysis of immunoglobulin heavy
chain configuration of leukemias. Three B220/
CD19/CD4 leukemias demonstrate germline
(GL) configuration; four B220/CD19/CD4 leu-
kemias demonstrate a recombined pattern. One
displays a monoclonal (M) and four an oligoclo-
nal (O) pattern. As a control for DNA quality and
loading, the blot was stripped and reprobed for
MCL-1, shown at bottom.
C: Spectral karyotype of a leukemia demonstra-
ting a clonal abnormality. Shown is the dominant
karyotype: 42, XY, 6, 12.
lymphoma in doxycycline-treated mice possessed human Treatment with doxycycline once again eliminated the leukemic
cells from the blood (Figure 6C) and substantially extendedBCL-2 expression, ruling out an escape from doxycycline regu-
lation as the explanation for progression in the majority of tumors survival in all the recipient groups (Figure 6D).
(Figure 6B). A unique Ig gene rearrangement, distinct from the
original tumor, was noted in a late-onset lymphoma of a doxycy- Differential sensitivity of mitochondria from
cline-treated mouse supporting the emergence of a clonally lymphoblastic leukemias versus nonmalignant
distinct tumor (Figure 6E). In summary, the late-onset B cell FL5.12 cells to BAX oligomerization
lymphomas that follow ablation of BCL-2 expression resemble and cytochrome c release
E-myc driven lymphomagenesis. This is consistent with the The rapid induction of apoptosis that proved coordinate with
emergence of independent lymphomas, although a clonal rela- the elimination of BCL-2 in the triply transgenic lymphoblasts
tionship with the initial leukemia can not be completely excluded prompted us to assess whether overexpressed BCL-2 was se-
with available technologies. Such E-myc-expressing tumors questering BH3-only proteins that were chronically activated by
could be expected to acquire a complementary aberration in myc-driven oncogenesis. To test this, we purified mitochondria
apoptosis; however, these spontaneous, secondary events from FL5.12 (a nonmalignant pro-B lymphocyte line) and from
would not be under the control of doxycycline. triply transgenic pro-B lymphoblastic leukemia cells to compare
their differential susceptibility to apoptosis. An “activating” BH3
domain (BIM) induced the activation and oligomerization of BAXThe transplantable leukemia is susceptible
to doxycycline ablation of BCL-2 and BAK and resulted in release of cytochrome c from normal
FL5.12 mitochondria and leukemia mitochondria (Figures 7AThe transplantability of a tumor is a standard measure of its
malignant potential. Three cohorts of sublethally irradiated (650 and 7B; Letai et al., 2002; Wei et al., 2001). In contrast, a “sensi-
tizing” BH3 domain (BAD) cannot activate BAX or BAK directly,rad) recipient mice received from 1.0  106 to 2.5  106 bone
marrow cells from triply transgenic donor mice with pre-pro-B but does bind antiapoptotic BCL-2 with high affinity and will
displace other activator BH3 peptides present in the BCL-2or pre-B cell leukemia. In each cohort, bone marrow cells from
leukemic mice, when injected into irradiated recipient mice, pocket (Letai et al., 2002; Wei et al., 2001). Whereas FL5.12
mitochondria are unaffected, the mitochondria from the lymph-transferred a lethal lymphoblastic leukemia (Figures 6C and 6D).
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Figure 4. Removal of BCL-2 induces remission of
leukemia and improves survival
A: Anti-human BCL-2 immunoblot. The four lanes
demonstrate decreasing BCL-2 levels in circulat-
ing mononuclear cells over 3 days following
doxycycline administration, in correlation with
the WBC (103/l).
B: Loss of BCL-2 normalizes the WBC in the 28
mouse cohort.
C and D: Peripheral blood smear of a triply trans-
genic mouse before (C) and 4 weeks after (D)
treatment with doxycycline.
E: Bone marrow of leukemic mouse demonstra-
ting replacement by a monotonous lymphoblast
population with frequent mitotic figures (HE).
F: Bone marrow of previously leukemic mouse
14 days after initiation of doxycycline treatment
(HE). Normal proportions of megakaryocytes,
erythroid progenitors, and granulocyte precur-
sors are now present.
G: Spleens from triply transgenic littermates at 7
weeks of age, in which the mouse on the right
was given doxycycline 500 g/ml in drinking wa-
ter starting at 5 weeks of age.
oblastic leukemia cells release cytochrome c in response to Discussion
sensitizing BAD BH3 as well as activating BIM BH3 (Figures 7A
Abnormalities in genes affecting apoptosis have been foundand 7B). Consistent with this, the sensitizing BAD BH3 domain
in nearly every cancer, suggesting they may be necessary toinduces the oligomerization of BAX in mitochondria from lymph-
develop cancer (Green and Evan, 2002; Hanahan and Weinberg,oblastic leukemia cells, but not the mitochondria from normal
2000; Schmitt, 2003). Consequently, the apoptotic pathway in-pro-B cells (Figure 7B). These data support the hypothesis that
cluding BCL-2 is a prominent target for drug development. Ain the leukemic cells, but not the nonmalignant FL5.12 cells,
BCL-2, is sequestering significant quantities of chronically acti- principal mechanism whereby BCL-2 protects cells includes
binding and sequestering “BH3-only” molecules, thereby pre-vated BH3 proteins.
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Figure 5. Leukemic cells die an apoptotic death when BCL-2 expression is eliminated
A: TUNEL staining of bone marrow from a leukemic mouse, methyl green counterstain.
B: TUNEL staining of a leukemic mouse 48 hr after addition of doxycycline to drinking water. Arrows indicate selected loci of TUNEL-positive leukemic cells
undergoing apoptotic death. Insets for A and B contain an HE stained serial section demonstrating replacement of marrow with leukemic cells. The
mean number of TUNEL-positive cells per 40 field from the untreated (7.9) and doxycycline-treated (77.3) marrows differ with a p value of .001.
C: Requirement for BCL-2 is autonomous to leukemia cells. Under normal culture conditions, the cell count more than tripled over 6 days. Treatment with
doxycycline (1 g/ml) induced death of 90% of the cultured cells as determined by trypan blue dye exclusion.
Figure 6. Elimination of BCL-2 expression extends
survival of leukemic mice
A: Kaplan-Meier survival plot of treated and un-
treated cohorts, demonstrating significant sur-
vival advantage following ablation of BCL-2 ex-
pression (p  0.000125). Leukemic mice treated
with doxycycline have a survival curve that is
indistinguishable from the myc-only cohort.
B: Lymphomas arising in doxycycline-treated
mice usually lack human BCL-2 transgene ex-
pression. First three lanes contain lysates of leuke-
mias from untreated triply transgenic mice. Next
7 lanes contain lysates of a lymphomas found in
mice treated with doxycycline. BCL-2 immu-
noblot shown at top, actin immunoblot shown
below.
C: The leukemia is transplantable, and the leuke-
mia is prevented by doxycycline treatment.
Bone marrow cells from a leukemic mouse were
injected intravenously into 13 sublethally irradi-
ated (650 rad) recipients. WBC of untreated
mice (black symbols) or mice treated with doxy-
cycline (500 g/ml) administered in the water
on the day of transplantation (red symbols) are
presented.
D: Transplanted mice die of leukemia, while
doxycycline-treated recipients display pro-
longed survival. Shown is one representative co-
hort of three independent transplant experi-
ments that received 2.4 106 bone marrow cells
from a donor with pre-B cell leukemia. Irradiated
control mice that were not transplanted sur-
vived 1 year.
E: Emergence of a distinct clone in a doxycy-
cline-treated late-onset B cell lymphoma. South-
ern blot of immunoglobulin heavy chain gene
configuration. Lane D, germline configuration of
donor leukemic bone marrow. Lanes 1 and 2,
bone marrows of late-onset lymphoid malignan-
cies in doxycycline-treated transplant recipients.
Lane 2 shows a new clonal rearrangement.
Lanes 3 and 4, bone marrow (BM) and lymph
node (LN) from untreated recipient mice that
rapidly succumbed to leukemia and display the
germline configuration of the donor cells.
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BCL-2 would prove toxic to cancer cells. Bcl-2-null mice, while
they display developmental kidney defects and loss of lympho-
cytes and melanocytes over time, do suggest that pharmaco-
logic inhibition of BCL-2 may be tolerated by normal tissues for
defined periods (Veis et al., 1993). Other models conditional
for the expression of transforming oncogenes including MYC
(Felsher and Bishop, 1999; Pelengaris et al., 1999), RAS (Chin
et al., 1999), BCR-ABL (Huettner et al., 2000), and WNT (Gunther
et al., 2003) have witnessed tumor regression when the onco-
gene expression was eliminated. The BCL-2 conditional allele
examined here provides the first clear evidence that an apopto-
sis regulator is required for tumor maintenance.
Why is the lymphoblastic leukemia here so singularly depen-
dent upon BCL-2? One model would hold that the initiating
oncogenic event is sacrosanct, a version of a synthetic lethal
mutation (Hartwell et al., 1997). The overexpression of BCL-2,
like the t(14;18) in human follicular lymphoma, occurs first. Sub-
sequent complementary mutations would reside in other path-
ways and actually depend on the presence of BCL-2, making
BCL-2 inviolate. A second, more broadly applicable model
argues that inherent to the transformation process, all can-
cers violate physiological checkpoints that would normally trig-
ger their demise, unless neutralized by an essential apoptotic
defect(s) (Figure 7C). The latter model predicts that whether
acquired early or late, aberrations in apoptosis constitute a
vulnerable target for therapeutic intervention that might prove
common to all cancers. For example, BAD sensitizing BH3 do-
main, which binds BCL-2, initiates a displacement reaction that
results in the activation of BAX on the mitochondria from malig-
nant cells, but not nonmalignant counterparts (Figures 7A and
7B). This provides a plausible explanation as to why the ablationFigure 7. Models of BCL-2 dependence in cancer
of BCL-2 is singularly effective in inducing apoptosis and remis-A: Mitochondria from cancer cells are selectively sensitized to BCL-2 antago-
nism. Mitochondria were isolated from a nonmalignant pro-B cell line sion of leukemia. Either elimination of BCL-2 or its inhibition by
(FL5.12) or from a mouse pro-B lymphoblastic leukemia. Mitochondria were a BH3 mimetic would release BH3-only proteins, constitutively
treated with 10 M (leukemia) or 30 M (FL5.12) BIM BH3 or 100 M BAD
present in cancer cells, which are capable of activating BAX,BH3 peptides or a solvent only 1% DMSO central. The sensitizer BAD BH3
promotes cytochrome c release only from the malignancy-derived mito- BAK. Our data support a model in which cancer cells are subject
chondria. Shown are representative examples of at least three independent to tonic death signaling, which must be opposed by an apoptotic
experiments. defect to maintain cancer cell survival. In the case of this mouseB: Mitochondria treated as in A were examined for oligomerization of BAX,
model, it is likely that MYC itself is responsible for some of thewhich correlates with cytochrome c release. Following peptide treatment
and BMH crosslinking, an immunoblot against BAX was performed. death signaling, either directly or indirectly inducing “BH3-only”
C: Schematic representation of the requirement for BCL-2 in tumor main- genes (Iaccarino et al., 2003). The leukemia model here provides
tenance. Left, overexpressed antiapoptotic BCL-2 is required for tumor
an initial proof of concept that a cancer can be killed by correct-maintenance. Right, removal (or antagonism) of BCL-2 releases BH3-only
ing an apoptotic defect.molecules resulting in the activation, oligomerization of multidomain pro-
apoptotic BAK or BAX, the permeabilization of the mitochondrial outer
membrane, cytochrome c release, and apoptotic death. Genetic aberra- Experimental procedures
tions inherent to cancer cells violate physiological checkpoints that chroni-
cally activate BH3-only molecules, which are bound and sequestered by Production of transgenic mice
BCL-2, protecting BAK, BAX from activation.
A DNA construct containing DMT targeting sequences, a minimal CMV
promoter, and the tet operator sequences was electroporated into an SV129/
Jae ES cell line. The selectable marker was removed by transient expression
of cre-recombinase. Correctly targeted ES cells were injected into blasto-
venting the activation of the lethal proapoptotic effectors BAX cysts. Chimeric progeny were bred to B6 mice and the targeted allele propa-
gated through the germline.and BAK (Cheng et al., 2001; Wei et al., 2001). Accordingly,
considerable efforts are underway to develop peptidomimetics
Monitoring leukemiathat mimic BH3 domains (Letai et al., 2002; Wang et al., 2000b)
Leukemia was diagnosed by examination of peripheral blood smears (Dipto screen and refine small molecules that occupy the BCL-2
Quick, JorVet J-322). White blood counts (WBC) were determined by an
pocket (Belli et al., 2003; Kim et al., 2001; Tzung et al., 2001; automated Coulter counter or confirmed by manual counts, which gave
Wang et al., 2000a) or to regulate BCL-2 by antisense ap- comparable results. Manual counts were performed by examining peripheral
proaches (Waters et al., 2000). Our model provides strong sup- blood from a razor-nicked tail diluted in buffer (saponin 0.3%, Hoechst 33258
1g/ml, EDTA 25 mM in phosphate-buffered saline) using a hemacytometer.port for the heretofore untested supposition that antagonism of
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Histological analysis and immunohistochemistry American Society for Hematology Scholar Award Program and the Claudia
Adams Barr Foundation. This work is also supported by NIH grants #P01Tissue samples were fixed in formalin and embedded in paraffin. BCL-2
immunoperoxidase staining used the DAKO #M0887 mouse monoclonal CA92625 and #K08 CA10254. A.L. is a Leukemia and Lymphoma Society
Fellow. S.J.K. serves on the scientific advisory board of IDUN Pharmaceuti-anti-human BCL-2 antibody.
cals, a nonpublic company developing cell death therapeutics.
Leukemic cell culture
Leukemic cells from bone marrow were grown in IMDM supplemented with
10% fetal calf serum, IL-7 10 ng/ml, FLT-3 ligand 5 ng/ml, and SCF 10
ng/ml. Received: May 5, 2004
Revised: July 2, 2004
TUNEL staining Accepted: July 8, 2004
Formalin-fixed, paraffin-embedded sections were stained using the In Situ Published: September 20, 2004
Death Detection Kit, AP (Roche).
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